CD8A and neoplasm: In the future, exploring and identifying biomarkers that can predict the risk of HPD in response to ICI treatment, preventing the occurrence of HPD by exhausting CD8+ T cells, and overcoming tumor immune resistance to prevent tumor metastasis and recurrence, holds significant clinical significance.